A Long-term Study of KT-621 Administered Orally to Participants with Asthma Previously Enrolled in a KT-621 Asthma Study
Key facts
- Where
- Bialystok, Gdansk, Lodz, Łódź, Poznan, Sosnowiec, Tarnów, Trzebnica, Wroclaw és Zawadzkie, LengyelországSee the 12 sites
- Phase
- 2. fázis
Where in Lengyelország
- Bio Zdrowie Sp. z o.o.Bialystok, LengyelországToborzás még nem indult
- Homeo Medicus Szczesiul sp.j.Bialystok, LengyelországToborzás még nem indult
- Clinica Vitae Sp. z o.o.Gdansk, LengyelországToborzás még nem indult
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej Uniwersytecki Szpital Kliniczny Nr 1 Im. Norberta Barlickiego Uniwersytetu Medycznego W LodziLodz, LengyelországToborzás még nem indult
- Umed Clinical Trials Sp. z o.o.Lodz, LengyelországToborzás még nem indult
- Santa Familia PTG ŁódźŁódź, LengyelországToborzás még nem indult
- Alergologia Plus sp. z o.o.Poznan, LengyelországToborzás még nem indult
- Kiepury Clinic Malgorzata Jarnot Specjalistyczna Praktyka Ginekologiczno-PołożniczaSosnowiec, LengyelországToborzás még nem indult
- CenterMed Sp. z o.o.Tarnów, LengyelországToborzás még nem indult
- Viltis Medica Sp. Z o.o.Trzebnica, LengyelországToborzás még nem indult
- Lekarze Specjalisci - J. Malolepszy I PartnerzyWroclaw, LengyelországToborzás még nem indult
- Centrum Medyczne Lucyna Andrzej Dymek s.c.Zawadzkie, LengyelországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kymera Therapeutics Inc.
- Trial code
- EU 2026-526241-98-00
- Record updated
- 2026. szeptember 23.
- Original description
To evaluate the long-term safety and tolerability of KT-621 in participants with asthmaRead full original descriptionShow less
A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
To evaluate the long-term safety and tolerability of KT-621 in participants with asthma
Inclusion: Must have completed all visits of the parent study, per its protocol, up to the end of treatment (EoT) visit; Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol; Must agree to contraceptive requirements in compliance with the clinical study and local requirements.
Exclusion: Must not have experienced any clinically significant change in health status during the parent study, which, in the opinion of the Investigator, would interfere with participant safety, study evaluations, or compliance with study procedures; or otherwise make the participant unsuitable for participation in this study; Must not have developed an AE during the parent study, that in the opinion of the Investigator or of the Sponsor's Medical Monitor, could indicate that continued treatment may present an unreasonable risk for the participant; Must not have met permanent discontinuation criteria and/or permanently discontinued study treatment for any reason during the parent study; Must not be a member of the Sponsor or site's investigational team or their immediate family; Must not be unsuitable to enter the study for any other reason, as judged by the Investigator, including potential risk of noncompliance to study procedures.